EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dimethyl Fumarate Treatment for Psoriasis in Real-World Clinical Practice: An Analysis from the Swiss Registry

Lara Valeska Maul, Melike Ak, Sara E Cerminara, Dario Simic, Elisabeth Victoria Gössinger, Elisabeth Roider, Anna Darzina, Alexander Zink, Iker Oyanguren Monferrer, Felix Oestereich, Eva Mateu, Alexander A Navarini und 2 weitere

Dermatology · 2025

DOI: 10.1159/000548354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, 2025. Verfasst von Lara Valeska Maul und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Psoriasis, Dimethyl Fumarate, Dermatologic Agents, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Limited data are available on the effectiveness and safety of dimethyl fumarate (DMF) for the treatment of moderate-to-severe psoriasis in real-world clinical practice. The objectives were to assess the effectiveness and safety of DMF in patients with moderate-to-severe plaque psoriasis in Switzerland.

Methods

Data from 28 adults enrolled in the Swiss Dermatology Network for Targeted Therapies registry who started DMF treatment as first line or subsequence therapy at registry entry and had ≥3 months of follow-up were analysed. No missing imputation was performed.

Results

The median Psoriasis Area and Severity Index (PASI) decreased from 9.3 to 2.0 (p = 0.0136) and 2.3 (p = 0.0156) after 6 and 12 months of DMF treatment, respectively. At month 6, 61.5%/61.5%/15.4% of patients achieved a PASI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisDimethyl FumarateDermatologic AgentsImmunosuppressive AgentsHumansRegistriesMaleFemaleMiddle AgedAdultSwitzerlandSeverity of Illness IndexTreatment OutcomeAged

Stichwörter der Autor:innen

Dimethyl fumaratePsoriasisReal worldRegistry

Substanzen

Dimethyl FumarateDermatologic AgentsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Basel, Basel, Switzerland.
  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Swiss4ward, Alicante, Spain.
  • Department of Dermatology and Allergy, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
  • Almirall AG, Wallisellen, Switzerland.

Zitieren

APA

Maul, L. V., Ak, M., Cerminara, S. E., Simic, D., Gössinger, E. V., Roider, E., Darzina, A., Zink, A., Oyanguren Monferrer, I., Oestereich, F., Mateu, E., Navarini, A. A., Kündig, T., & Maul, J. T. (2025). Dimethyl Fumarate Treatment for Psoriasis in Real-World Clinical Practice: An Analysis from the Swiss Registry. Dermatology. https://doi.org/10.1159/000548354

Vancouver

Maul LV, Ak M, Cerminara SE, Simic D, Gössinger EV, Roider E, et al. Dimethyl Fumarate Treatment for Psoriasis in Real-World Clinical Practice: An Analysis from the Swiss Registry. Dermatology. 2025. doi:10.1159/000548354

BibTeX
@article{Maul2025,
  author = {Maul, Lara Valeska and Ak, Melike and Cerminara, Sara E and Simic, Dario and Gössinger, Elisabeth Victoria and Roider, Elisabeth and Darzina, Anna and Zink, Alexander and Oyanguren Monferrer, Iker and Oestereich, Felix and Mateu, Eva and Navarini, Alexander A and Kündig, Thomas and Maul, Julia-Tatjana},
  title = {Dimethyl Fumarate Treatment for Psoriasis in Real-World Clinical Practice: An Analysis from the Swiss Registry},
  journal = {Dermatology},
  year = {2025},
  doi = {10.1159/000548354}
}
Kostenlos starten →